Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-01-26 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
UPDATE ON EVUSHELD US EUA
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the FDA Emergency Use Authorization status of Evusheld, including regulatory and clinical trial information. The document does not contain comprehensive financial statements or detailed financial performance data. It is a regulatory update filing rather than a full financial report or earnings release. The length is 8301 characters, which is moderate, but the content is primarily regulatory and informational about product authorization status and clinical trials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-26 English
Update on Evusheld US EUA
Regulatory Filings Classification · 100% confidence The document begins with 'National Storage Mechanism' and prominently features the 'RNS Number' and the date/time stamp typical of regulatory news services. The content is an update regarding the FDA's decision on Evusheld, which is a material event concerning a product's regulatory status. The document concludes with boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and the FCA. This structure strongly indicates a regulatory announcement disseminated via the RNS system. Since it is a specific announcement about a regulatory/product development event and not a comprehensive financial report (like 10-K or IR) or a general management change, the most appropriate classification is the general regulatory filing category, RNS, as it serves as the primary channel for such immediate, non-standardized disclosures.
2023-01-26 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-01-24 English
SC TO-T Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing with the SEC, which is a Tender Offer Statement under Rule 14d-100 of the Securities Exchange Act of 1934. It relates to a tender offer by AstraZeneca and its subsidiaries to purchase shares of CinCor Pharma, Inc. The document includes detailed information about the terms of the offer, the parties involved, and related agreements such as the Merger Agreement. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing specifically related to a tender offer transaction. This matches the definition of M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids. The document is lengthy and substantive, not a mere announcement or certification, so it is not classified as RNS or RPA. Therefore, the correct classification is TAR with high confidence.
2023-01-23 English
ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting the completion of the acquisition of Neogene Therapeutics. It details the acquisition terms, company background, and strategic rationale. Form 6-K is a report of foreign issuers used to disclose material information between annual reports. The content focuses on a corporate acquisition announcement rather than a full annual or quarterly financial report, audit, or earnings release. It is not a proxy, voting result, or management change announcement. The document is a regulatory filing reporting a material corporate event. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6194 characters) and content confirm it is not merely an announcement of a report but a substantive filing about the acquisition event.
2023-01-17 English
Acquisition of Neogene Therapeutics completed
M&A Activity Classification · 99% confidence The document is clearly identified as an 'RNS Number' announcement from AstraZeneca PLC, dated January 16, 2023. The content details the completion of an acquisition (AstraZeneca acquiring Neogene Therapeutics) and provides financial considerations. This type of announcement, which reports a significant corporate event (like an acquisition) via the Regulatory News Service (RNS) system, fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (10-K, IR), management discussion (MDA), or a dedicated M&A filing (TAR), but rather a broad regulatory disclosure. Given the presence of the RNS header and the nature of the announcement (corporate action disclosure), RNS is the most appropriate classification.
2023-01-16 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.